Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of rufinamide (E2080) in Lennox–Gastaut syndrome
jRCT2080221207Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rufinamide in Lennox-Gastaut syndrome (LGS), sponsored by Eisai Co., Ltd. Primary endpoint: Long-term safety and tolerability of rufinamide. Started Aug 2010; status: completed.
02
Drugs
rufinamide
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on jRCT2080221207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221207.